MetaVia is preparing to compare its experimental obesity drug with one of the most closely watched molecules in the field: Eli Lilly’s retatrutide.
At ObesityWeek 2026 in Washington, a researcher from South Korea’s Dong-A ST Research Center is scheduled to present a poster titled “DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide.”
Retatrutide is Lilly’s investigational triple-hormone injection. DA-1726 is a much earlier-stage GLP-1/glucagon dual agonist being developed by MetaVia, a Nasdaq-listed biotechnology company based in Cambridge, Massachusetts.
Putting retatrutide in the title is a statement of ambition. Whether it is supported by meaningful comparative evidence is a different question.
MetaVia’s November 9 announcement gives the poster’s title, presenter and schedule. It does not disclose the numerical comparison, experimental model, doses or duration of the work. The presentation is scheduled for November 14, 2026, at 7:30 p.m. Eastern.
Until those data are available, the title is a company-backed claim about results that readers cannot independently examine.
What can be examined is the human Phase 1 data MetaVia released on November 5.
After approximately 16 weeks, 15 participants receiving DA-1726 had lost an average of 11.9% of their body weight. The four-person placebo group gained approximately 1.6%, producing a reported placebo-adjusted difference of 13.5 percentage points.
Those are encouraging early results. They are also based on fewer people than fit inside a small conference room.
A 13.5-point difference looks competitive. A four-person placebo arm makes the evidence considerably less secure than the headline suggests.
What the DA-1726 Phase 1 Trial Actually Showed
DA-1726 is a once-weekly injectable peptide developed as an analog of oxyntomodulin, a naturally occurring gut hormone involved in appetite and metabolic regulation.
The Phase 1 program, registered as NCT06252220, has examined the drug’s safety, tolerability, pharmacokinetics and early metabolic effects in adults with obesity.
The latest interim results came from Part 3B, a dose-titration cohort in which participants received 16 mg weekly for four weeks, then 32 mg for four weeks, followed by a target dose of 64 mg for another eight weeks.
MetaVia presented the findings at the Precision Liver Symposium in Denver on November 4 and published a detailed announcement the following day.
The interim efficacy analysis included 15 participants receiving DA-1726 and four receiving placebo.
At baseline, the treated participants weighed an average of 98.6 kilograms, or approximately 217 pounds.
By day 109, their reported average reduction was 12.19 kilograms, equivalent to 26.9 pounds and a mean percentage weight reduction of 11.9%.
In the placebo group, mean weight increased by approximately 1.35 kilograms, or 1.6%.
The resulting difference in mean percentage change between the two groups was 13.5 percentage points, with MetaVia reporting a p-value below 0.001.
The company also reported improvements in waist circumference, blood sugar measures and body composition.
Waist circumference decreased by an average of 9.6 centimeters in the treated group, while HbA1c, a measure of longer-term blood glucose, declined from 5.79% to 5.33%.
The HbA1c improvement was 0.24 percentage points greater than placebo, according to the company’s analysis. Participants did not have diabetes at study entry.
These are signals of metabolic activity, but this remains a small Phase 1 study rather than a trial designed to establish long-term effectiveness.
The placebo group is especially important. A comparison involving four people is vulnerable to individual variations in body weight, behavior, metabolism and study participation.
Even when statistical testing produces a low p-value, a small trial does not establish that a similar effect will appear in larger and more diverse populations.
The drug group lost 11.9% of body weight. The 13.5-point headline comes from comparing that loss with a placebo group of four people who gained weight.
Why a Glucagon Receptor Agonist Is Challenging Retatrutide
DA-1726 works through two hormone receptors: GLP-1 and glucagon.
GLP-1 receptor activation influences appetite, insulin secretion and blood glucose regulation. Glucagon receptor activation can influence energy expenditure and hepatic metabolism, although its effects depend on the molecule, dose and physiological setting.
MetaVia describes DA-1726 as engineered with a 3-to-1 potency ratio favoring GLP-1 receptor activity over glucagon receptor activity.
That is a description of the molecule’s pharmacological design, not a guarantee that clinical effects occur in the same numerical ratio.
The premise is to combine appetite suppression with additional metabolic activity, particularly in the liver and adipose tissue.
That pairing has attracted substantial interest across the peptide industry.
Boehringer Ingelheim and Zealand Pharma are developing survodutide, another GLP-1/glucagon dual agonist. Its development program is considerably further advanced, with Phase 3 obesity results and cardiovascular safety evidence already available.
Grey Pepper covered the benefits and limitations of that approach in its analysis of survodutide’s Phase 3 weight-loss results and gastrointestinal side effects.
Altimmune’s pemvidutide also targets both receptors and has generated research data in liver disease and alcohol use disorder, including the RECLAIM Phase 2 alcohol study.
Retatrutide goes further by activating three receptors: GIP, GLP-1 and glucagon.
That triple-agonist design has produced substantial weight-loss results in clinical trials and made retatrutide a prominent benchmark for investigational obesity therapies.
MetaVia is effectively asking whether its two-receptor formulation can deliver a sufficiently competitive metabolic effect without adding GIP activity.
But receptor count alone does not determine clinical effectiveness.
Two molecules can activate the same receptors yet differ substantially in receptor potency, signaling behavior, tissue exposure, dose escalation and tolerability.
The title of MetaVia’s upcoming poster suggests that DA-1726 and retatrutide produced comparable weight loss under some experimental conditions.
It does not establish that the two medicines deliver comparable weight reduction in humans.
MetaVia has not announced a randomized human head-to-head trial comparing DA-1726 with retatrutide.
Two receptors versus three is an interesting pharmacology question. It is not yet a demonstrated clinical contest.
The Liver Results May Matter More Than the Weight Loss
MetaVia’s strongest strategic argument for DA-1726 may not be its competition with obesity drugs.
It may be the drug’s activity in the liver.
In an MRI substudy of 12 participants receiving DA-1726 and four receiving placebo, MetaVia reported a 68% placebo-adjusted reduction in liver fat at day 109.
That figure requires explanation because it is easy to mistake it for a straightforward average reduction within the treatment group.
The 68% result came from a geometric mean ratio comparing the groups, with a reported ratio of 0.32. It is not the same as saying every patient, or the average treated patient, lost 68% of their baseline liver fat.
The treated group began with mean liver fat of 5.2%, compared with 8.0% in the placebo group.
The company reported an absolute treatment difference of 6.4 percentage points versus placebo, as well as a 40.4% relative increase in liver fat from baseline among placebo participants.
With only four placebo participants, that deterioration warrants attention when interpreting the adjusted effect.
There were more encouraging findings among participants who already had measurable hepatic steatosis.
Of the 12 treated participants undergoing MRI assessment, five had liver fat of at least 5% at baseline.
All five had liver fat readings below 5% by day 109, according to MetaVia.
In those five participants, mean MRI-measured liver fat declined from 8.3% to 3.0%, a reduction of 5.3 percentage points.
Across the larger 12-person MRI treatment subgroup, ten participants achieved a relative liver-fat reduction of at least 30%, compared with none of the four placebo participants.
Those findings suggest the compound has meaningful biological activity in the liver.
They do not establish that DA-1726 reverses liver fibrosis, prevents cirrhosis or reduces liver-related clinical events.
They also do not prove that its effect on liver fat is superior to established or investigational alternatives.
That distinction matters because liver-fat imaging is a surrogate measure. It can help researchers understand metabolic responses, but clinical benefit requires additional evidence.
MetaVia’s development plans suggest that management sees a larger opportunity in liver disease than in competing directly for the crowded general-obesity market.
The liver signal is potentially important. The clinical evidence is still far too small to call DA-1726 a liver-disease treatment.
Nearly Half the Treated Participants Reported Vomiting
The safety results complicate an otherwise encouraging early dataset.
Of the 15 participants receiving DA-1726, nine experienced gastrointestinal adverse events.
Seven participants, or 46.7%, reported vomiting.
Nausea, diarrhea and dyspepsia were each reported by two participants, corresponding to 13.3% of the treatment group for each event.
Constipation and abdominal pain were each reported by one participant.
The company described most gastrointestinal events as mild to moderate.
One serious adverse event involving severe vomiting was considered possibly related to DA-1726. That participant recovered, according to MetaVia.
No participants discontinued the study because of gastrointestinal adverse events.
MetaVia also reported no new gastrointestinal adverse events after week nine through the day-109 assessment.
That is potentially encouraging for treatment adaptation, but it should not be confused with evidence that earlier symptoms had universally disappeared or that side effects would remain manageable during longer treatment.
The dosing schedule reached 64 mg after eight weeks, and the relatively rapid escalation may be relevant to the observed gastrointestinal events.
Whether slower titration or alternative doses can preserve efficacy while improving tolerability requires further testing.
There is also an important body-composition qualification.
MetaVia reported larger reductions in adipose tissue than in lean tissue, including a 22% placebo-adjusted reduction in visceral adipose tissue and a 19% reduction in total measured adipose tissue.
However, total lean tissue was also 8% lower versus placebo, and thigh muscle volume was 9% lower.
That is relative preservation compared with fat reduction, not the absence of lean-tissue or muscle-volume loss.
Longer trials will need to clarify the clinical significance of these changes, particularly for patients whose nutritional status or muscle function is already compromised.
No one quit because of gastrointestinal side effects, but seven of fifteen treated participants reported vomiting. Both facts belong in the same sentence.
What the Retatrutide Comparison Must Prove
The ObesityWeek poster is scheduled for Saturday, November 14, during the Gut Peptides, Appetite Signaling & Novel Therapeutics session.
The presenting author is Il Hoon Jeong, a research scientist at Dong-A ST Research Center, and the presentation is listed as Poster-229.
The official conference schedule confirms the title and timing, but the numerical results had not been made publicly available in the materials reviewed for this article as of November 12.
That means several basic questions remain unanswered.
First is the experimental model. Did researchers compare the compounds in animals, cultured cells or another laboratory system?
A comparison in animals could provide useful evidence about mechanism or early metabolic effects. It would not establish equivalent efficacy in patients with obesity.
Second is dosing. Were the compounds compared at matched doses, matched exposures or separately optimized dose levels?
Those choices can substantially influence results and determine whether a comparison is scientifically informative.
Third is treatment duration. A short experiment may reveal differences in initial weight change without capturing longer-term tolerability, plateau effects or metabolic adaptation.
Fourth is the definition of the claimed distinct metabolic profile.
Does it refer to liver fat, glucose regulation, energy expenditure, fat distribution, lean tissue or another measured outcome?
Until the full poster is available, readers cannot determine how the comparison was constructed or how much confidence its conclusion deserves.
There is a further methodological issue.
Even if DA-1726 and retatrutide produce similar weight changes in an experimental model, that does not demonstrate clinical equivalence.
Establishing comparable efficacy in humans requires appropriately designed trials with sufficient participants, relevant endpoints and statistical methods capable of evaluating the comparison.
A conference poster can justify further investigation. It cannot substitute for such a trial.
For a small biotechnology company, naming a prominent rival in a scientific presentation can attract attention. But attention and clinical validation are different currencies.
The poster title makes the comparison. The actual data must earn it.
MetaVia’s Next Trial Is About Liver Disease, Not Retatrutide
Despite the prominent retatrutide comparison, MetaVia’s announced development strategy points toward liver-related metabolic disease.
The company plans a 48-week, non-biopsy Phase 2 study involving as many as 150 participants with metabolic dysfunction and alcohol-associated liver disease, known as MetALD, or alcohol-associated liver disease, known as ALD.
The study is targeted to begin in the second half of 2027.
MetaVia also expects to report the complete data from Phase 1 Parts 3A and 3B during the first quarter of 2027.
Neither development should be treated as complete until the company releases the results or confirms the study has begun.
For patients with alcohol-related or mixed-cause fatty liver disease, an effective metabolic treatment could have value beyond the amount of weight it produces.
But the present Phase 1 study enrolled adults with obesity who were otherwise described as healthy, not a large population with established MetALD or advanced alcohol-related liver disease.
That gap between the population studied and the population MetaVia eventually wants to treat is important.
Patients with liver disease may differ in nutritional status, metabolic complications, medication tolerance and underlying organ function.
The next studies will need to determine whether DA-1726’s early metabolic effects translate into clinically useful benefits in those populations.
They will also need to address the gastrointestinal tolerability observed during dose escalation and establish whether treatment can be sustained over longer periods.
MetaVia may eventually choose to compete in the general obesity market. But its current plans suggest that liver disease offers a more focused route for the program.
That may be strategically sensible for a small developer facing companies with much larger clinical programs, manufacturing resources and commercial organizations.
The larger lesson is that promising Phase 1 efficacy signals are beginning to appear across increasingly specialized peptide designs.
The difficult work remains proving that those signals persist in hundreds or thousands of patients and translate into outcomes beyond a short-term percentage on a scale.
For DA-1726, the human results so far are encouraging, the gastrointestinal side effects deserve scrutiny, and the liver findings justify further investigation.
What the evidence does not yet justify is calling it a clinical rival to retatrutide.
Fifteen treated participants can establish a reason to keep studying a drug. They cannot establish that it belongs in the same league as a late-stage obesity medicine.
Sources and Further Reading
- MetaVia — MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data, November 5, 2026.
- MetaVia / PR Newswire — MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek 2026, November 9, 2026.
- MetaVia — November 2026 Investor Presentation, furnished to the U.S. Securities and Exchange Commission, including Phase 1 Part 3B results.
- ClinicalTrials.gov — DA-1726 Phase 1 Clinical Trial Registration, NCT06252220.
- Peptide and Protein — MetaVia Will Compare DA-1726 With Retatrutide in an ObesityWeek Poster, November 9, 2026.
- Eli Lilly — What to Know About Retatrutide, medically reviewed October 2026.
